Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease

US6617309B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Roger D. Tung · Lexington, US
• Scott L. Harbeson · Cambridge, US
• David Deininger · New Brunswick, US
• Mark A. Murcko · Holliston, US
• Govinda Rao Bhisetti · Lexington, US
• Luc Farmer · Foxborough, US

Key dates

• Filing date: Jun 6, 2001
• Grant date: Sep 9, 2003
• Expiry date: Jul 2, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.